Pharmaids Pharmaceuticals Limited (BOM:524572)
India · Delayed Price · Currency is INR 39.87
+0.92 (2.36%)
At close: Feb 12, 2026
Pharmaids Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 247.46 | 194.47 | 151.12 | - | 39.39 | 85.51 |
Other Revenue | 0.66 | 0.66 | 1.88 | - | - | - |
| 248.12 | 195.14 | 153 | - | 39.39 | 85.51 | |
Revenue Growth (YoY) | -1.08% | 27.54% | - | - | -53.93% | - |
Cost of Revenue | 166.65 | 132.37 | 125.11 | 9.04 | 35.71 | 81.59 |
Gross Profit | 81.47 | 62.76 | 27.89 | -9.04 | 3.68 | 3.92 |
Selling, General & Admin | 159.31 | 144.25 | 97.01 | 13.06 | 0.67 | 0.83 |
Other Operating Expenses | 96.15 | 45.2 | 51.95 | 76.81 | 1.63 | 2.02 |
Operating Expenses | 278.79 | 213.85 | 166.22 | 90.04 | 2.4 | 3.3 |
Operating Income | -197.32 | -151.09 | -138.32 | -99.08 | 1.28 | 0.62 |
Interest Expense | -36.83 | -20.07 | -15.42 | - | - | - |
Interest & Investment Income | 0.29 | 0.29 | 0.28 | - | - | - |
Currency Exchange Gain (Loss) | -0.14 | -0.14 | -0.45 | - | - | - |
Other Non Operating Income (Expenses) | 1.59 | -0.8 | 6.2 | -0 | 0.12 | 0.26 |
EBT Excluding Unusual Items | -232.41 | -171.81 | -147.71 | -99.08 | 1.4 | 0.88 |
Gain (Loss) on Sale of Investments | - | - | -0.32 | - | - | - |
Other Unusual Items | 30.36 | -0.98 | -8.18 | - | - | - |
Pretax Income | -202.05 | -172.79 | -156.21 | -99.08 | 1.4 | 0.88 |
Income Tax Expense | -45.82 | -37.74 | -37.78 | -23.52 | -0.05 | -0.05 |
Earnings From Continuing Operations | -156.24 | -135.05 | -118.43 | -75.56 | 1.45 | 0.93 |
Minority Interest in Earnings | 23.57 | 27.29 | 38.75 | - | - | - |
Net Income | -132.67 | -107.77 | -79.68 | -75.56 | 1.45 | 0.93 |
Net Income to Common | -132.67 | -107.77 | -79.68 | -75.56 | 1.45 | 0.93 |
Net Income Growth | - | - | - | - | 55.55% | 178.26% |
Shares Outstanding (Basic) | 38 | 35 | 23 | 13 | 10 | 10 |
Shares Outstanding (Diluted) | 38 | 35 | 23 | 13 | 10 | 10 |
Shares Change (YoY) | 38.67% | 55.24% | 76.16% | 25.07% | - | - |
EPS (Basic) | -3.52 | -3.06 | -3.51 | -5.86 | 0.14 | 0.09 |
EPS (Diluted) | -3.52 | -3.06 | -3.51 | -5.86 | 0.14 | 0.09 |
EPS Growth | - | - | - | - | 55.56% | 200.01% |
Free Cash Flow | -289.24 | -264.72 | -334.82 | -56.92 | -2.59 | 4.04 |
Free Cash Flow Per Share | -7.67 | -7.51 | -14.74 | -4.41 | -0.25 | 0.39 |
Gross Margin | 32.84% | 32.16% | 18.23% | - | 9.34% | 4.58% |
Operating Margin | -79.53% | -77.43% | -90.41% | - | 3.25% | 0.73% |
Profit Margin | -53.47% | -55.23% | -52.08% | - | 3.69% | 1.09% |
Free Cash Flow Margin | -116.57% | -135.66% | -218.84% | - | -6.58% | 4.72% |
EBITDA | -175.33 | -128.03 | -121.07 | -98.91 | 1.36 | 1.07 |
EBITDA Margin | -70.66% | -65.61% | -79.13% | - | 3.46% | 1.25% |
D&A For EBITDA | 21.99 | 23.06 | 17.25 | 0.17 | 0.08 | 0.45 |
EBIT | -197.32 | -151.09 | -138.32 | -99.08 | 1.28 | 0.62 |
EBIT Margin | -79.52% | -77.43% | -90.41% | - | 3.25% | 0.73% |
Revenue as Reported | 250.89 | 195.51 | 159.9 | - | 39.54 | 85.77 |
Advertising Expenses | - | 1.34 | 0.15 | 0 | 0.11 | 0.15 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.